KHTRF News and Press, Knight Therapeutics Inc From 12/19/23

MONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Supernus"), a biopharm...

2023-11-12 01:42:09 ET Knight Therapeutics Inc. (KHTRF) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Samira Sakhia - President and Chief Executive Officer Arvind Utchanah - Chief Financial Officer Conference Call Participant...

MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2023. All currency amounts ar...

MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Following the re...

MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Mar...

MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, t...

MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Compani...

2023-08-10 12:36:09 ET Knight Therapeutics, Inc. (KHTRF) Q2 2023 Earnings Conference Call August 10, 2023, 08:30 ET Company Participants Samira Sakhia - President, CEO & Director Arvind Utchanah - CFO Amal Khouri - Chief Business Officer Conference Call...

2023-08-10 09:18:15 ET Knight Therapeutics press release ( OTCPK:KHTRF ): Q2 GAAP EPS of C$0.02. Revenue of C$89.9M (+18.6% Y/Y). For further details see: Knight Therapeutics GAAP EPS of C$0.02, revenue of C$89.9M

MONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2023. All currency amounts are in...